A viable alternative for editor delivery
- PMID: 37651157
- PMCID: PMC10934309
- DOI: 10.1182/blood.2023021309
A viable alternative for editor delivery
Conflict of interest statement
Conflict-of-interest disclosure: D.E.B. is an inventor of patents related to therapeutic gene editing and has consulted for Kytopen. F.E. declares no competing financial interests.
Figures
Comment on
-
Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells.Blood. 2023 Aug 31;142(9):812-826. doi: 10.1182/blood.2022019333. Blood. 2023. PMID: 37294917 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources